Supernus Submits NDA for SPN-830 for Continuous Treatment of ON-OFF Episodes in Adults with Parkinson’s Disease Who Have Failed Two Treatments
September 14, 2020 08:15 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
September 09, 2020 16:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Present at the Wells Fargo Virtual Health Care Conference
September 02, 2020 16:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Second Quarter 2020 Financial Results
August 18, 2020 18:06 ET
|
Supernus Pharmaceuticals, Inc.
Total revenue of $126.7 million, including net product sales of $89.7 million for Trokendi XR®, $23.7 million for Oxtellar XR®, and $10.6 million for the acquired Parkinson’s disease (PD)...
Supernus Announces Preliminary Second Quarter 2020 Revenue
August 11, 2020 16:30 ET
|
Supernus Pharmaceuticals, Inc.
Second quarter total revenue is estimated to be $126.7 million, a 21% increase over 2019Net product sales of Trokendi XR® and Oxtellar XR® are estimated to be $113.4 million, an 11% increase over...
Supernus Sues Apotex for Infringement of Oxtellar XR® Patents
June 26, 2020 18:29 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., June 26, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Completes Acquisition of CNS Portfolio from US WorldMeds
June 09, 2020 15:46 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., June 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Present at the Jefferies Virtual Health Care Conference
May 27, 2020 16:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., May 27, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Paragraph IV ANDA Filing for Oxtellar XR®
May 15, 2020 16:15 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., May 15, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces First Quarter 2020 Financial Results
May 05, 2020 18:46 ET
|
Supernus Pharmaceuticals, Inc.
First quarter total revenue of $95.0 million, an 11% increase over 2019First quarter net product sales of $92.5 million, an 11% increase over 2019First quarter operating earnings of $29.0 million, a...